Proteomics Approaches to Identify Tumor Antigen Directed Autoantibodies as Cancer Biomarkers
Open Access
- 1 January 2004
- journal article
- review article
- Published by Wiley in Disease Markers
- Vol. 20 (3) , 149-153
Abstract
The identification of autoantibodies to tumor cell proteins by proteomics approaches has great potential impact on cancer biomarker discovery. The humoral immune response represents a form of biological amplification of signals that are otherwise weak due to very low concentrations of antigen, especially in the early stages of cancers. In addition, proteomics can detect immunoreactivity directed against protein post‐translational modifications. Two‐dimensional gel based Western blots, protein antigen microarrays, and multiplex ELISA reactions have been applied by our group to antigen based biomarker detection and validation. The latter two are based on liquid‐phase separations that are suitable for automation. This work has resulted in the identification of numerous cancer biomarker candidates. Large clinical studies are currently planned to establish their value in early cancer diagnosis.Keywords
Funding Information
- Michigan Life Sciences Corridor (MEDC-238)
This publication has 12 references indexed in Scilit:
- Development of Natural Protein Microarrays for Diagnosing Cancer Based on an Antibody Response to Tumor AntigensJournal of Proteome Research, 2004
- Methods and applications of antibody microarrays in cancer researchProteomics, 2003
- Molecular profiling of the immune response in colon cancer using protein microarrays: Occurrence of autoantibodies to ubiquitin C‐terminal hydrolase L3Proteomics, 2003
- Protein arrays for autoantibody profiling and fine‐specificity mappingProteomics, 2003
- Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivityProteomics, 2003
- Harnessing immunity for cancer marker discoveryNature Biotechnology, 2003
- Fingerprinting the circulating repertoire of antibodies from cancer patientsNature Biotechnology, 2002
- An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancerProceedings of the National Academy of Sciences, 2001
- New Paths in Human Cancer SerologyJournal of Experimental Medicine, 1998
- The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapyImmunology Today, 1996